Enveda Biosciences has raised a $51M Series B funding round to develop plant-based therapies.
Since its inception in 2019, the company has raised $175M.
- Enveda is a drug discovery and development company that uses AI to research healing potential in plants.
- The company's proprietary platform aims to solve natural medicine development challenges such as:
- active molecule identification,
- property and structure prioritization,
- amenability to medicinal chemistry,
- and large-scale material access.
- Kinnevik led the funding round, with participation from FPV, True Ventures, Dimension, and Wireframe.
- The company aims to use this funding to boost its product development and launch the clinical trial process for its therapies.
- Enveda is based in Boulder, Colorado.
